Plné znění - 36/2019 Sb. m. s.

Sdělení o přijetí nového znění Přílohy I (Seznam zakázaných látek a metod dopingu pro rok 2018 - Mezinárodní standard)

36/2019 Sb. m. s.

Sdělení

INFORMACE

36

SDĚLENÍ

Ministerstva zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx xxxx x. 58/2007 Sb. x. x. x x. 46/2008 Sb. m. x.

Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, xx xxx 1. xxxxx 2017 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx xxxxxxx pro xxx 2018 - Xxxxxxxxxxx standard Mezinárodní xxxxxx proti xxxxxxx xx sportu¹⁾.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx republiky x xxxxxxxxx xxxxxxxxx podepsal xxxxxxx x přijetí xxxx Xxxxxxx I Xxxxxx republikou.

Nové xxxxx Xxxxxxx I xxxxxxxxx x xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx xxx 1. ledna 2018. Xxx Českou xxxxxxxxx vstoupilo xxxx xxxxx Xxxxxxx I x xxxxxxxx xxx 5. xxxxxx 2019.

Xxxx xxxxxx nového znění Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx I xxxxxx od 1. xxxxx 2017 a xxxxxxxxx pod č. 80/2017 Sb. m. s.

Xxxxxxxx xxxxx nového xxxxx Xxxxxxx I a xxxx xxxxxxx xx xxxxxxx jazyka xx xxxxxxxxx současně.

SVĚTOVÁ

ANTIDOPINGOVÁ

AGENTURA

SVĚTOVÝ XXXXXXXXXXXXX XXXXX

XXXXXX ZAKÁZANÝCH LÁTEK X METOD XXXXXXX XXX XXX 2018

XXXXXXXXXXX XXXXXXXX

Xxxxxxxxx text Xxxxxxx xxxx xxxxxxxxx XXXX x bude xxxxxxxxxx x xxxxxxxxxx x xxxxxxxxxxxxx.

X xxxxxxx xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxx x francouzskou xxxxx xxxx xxxxxxxxxxx xxxxxxxx xxxxx.

Xxxxx Seznam bude xxxxxx xx 1. xxxxx 2018 

XXXXXX XXXXXXXXXX XXXXX X XXXXX XXXXXXX XXX XXX 2018

XXXXXXX ANTIDOPINGOVÝ XXXXX

Xxxxxx xx 1. xxxxx 2018

XXXXX X XXXXXX XXXXXXXX XXXXX (XXX XXXXXXX X MIMO SOUTĚŽ)

Podle xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx xxxxxxx Xxxxxxxx látky budou xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" xxxxx xxxxx xx xxxxxx X1, X2, S4.4, X4.5 x X6(x) a Xxxxxxxxxx xxxxx M1, X2 x X3.

XXXXXXXX XXXXX

X0. NESCHVÁLENÉ XXXXX

Xxxxxxxxx xxxxxxxxxxxxx látka, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Seznamu x xxxx xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxx regulačním xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu xxxxxxx xxxx po ukončené xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx pouze xxx xxxxxxxxxxx xxxxxxx), xx zakázána xxxxx.

X1. XXXXXXXXXX LÁTKY

Anabolické xxxxx xxxx xxxxxxxx.

1. XXXXXXXXXX XXXXXXXXXX STEROIDY (AAS):

(a) Xxxxxxxx* XXX, xxxxxxxxxx:

1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3ß,17ß-xxxx);

1-xxxxxxxxxxxxx (5α-androst-1-en-3,17-dion);

1-androsteron (3α-xxxxxxx-5α-xxxxxxx-1-xx-17-xx);

xxxxxxxxx (xxxx-4-xx-3ß, 17ß-xxxx);

xxxxxxxxxx;

xxxxxxx ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol);

dehydrochlormethyltestosteron (4-xxxxxx-17ß-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx);

xxxxxxxxxxxxxxxxxxxxxxx (17α-methyl-5α-androst-2-en-17ß-ol);

drostanolon;

ethylestrenol (19-xxxxxxxxx-4-xx-17α-xx);

xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx (17α-xxxxxx[1,2,5]xxxxxxxxxx[3',4':2,3]-5α-xxxxxxxxx-17ß-xx);

xxxxxxxxx;

4-xxxxxxxxxxxxxxxxxx (4,17ß-dihydroxyandrost-4-en-3-on);

kalusteron;

klostebol;

mestanolon;

mesterolon;

metandienon (17ß-hydroxy-17α-methylandrosta-1,4-dien-3-on);

metenolon;

methandriol;

metasteron (17ß-xxxxxxx-2α,17α-xxxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx);

xxxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx);

xxxxxXxxxxxxxxxxx;

xxxxxxxxxx (xxxxxxxxxxxxxxx (17ß-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxx (17ß-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxxx);

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

1-xxxxxxxxxxx (17ß-xxxxxxx-5α-xxxxxxx-1-xx-3-xx);

xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18α-xxxx-19-xxx-17α-xxxxxx-4,9,11-xxxxx-3-xx);

xxxxxxxxx (17ß-xxxxxxxxxxx-4,9,11-xxxxx-3-xx);

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx.

x. Xxxxxxxxx** XXX, pokud xxxx xxxxxx xxxxxxxx:

Xxxxxxxxxxxxx (5α-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5α-xxxxxxxxx-3-xx);

xxxxxxxxxxxxx (androst-5-en-3ß,17ß-diol);

androstendion (xxxxxxx-4-xx-3,17-xxxx);

xxxxxxxx;

xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx);

xxxxxxxxx;

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx);

xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-xxxxxxxxxxxxxx-5-xx-17-xx);

xxxxxxxxxxx;

x xxxxxx metabolity x xxxxxxx, včetně, xxx xx s xxxxxxxx xxxxx xx xx:

5α-xxxxxxxxx-3α,17α-xxxx;

5α-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxxxx-3ß,17α-xxxx;

5α-xxxxxxxxx-3ß,17ß-xxxx;

5ß-xxxxxxxxx-3α,17ß-xxxx;

5α-xxxxxxx-2-xx-17-xx;

xxxxxxx-4-xx-3α,17α-xxxx;

xxxxxxx-4-xx-3α,17ß-xxxx;

xxxxxxx-4-xx-3ß,17α-xxxx;

xxxxxxx-5-xx-3α,17α-xxxx;

xxxxxxx-5-xx-3α,17ß-xxxx;

xxxxxxx-5-xx-3ß,17α-xxxx;

4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3ß,17ß-xxxx);

5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx);

xxxxxxxxxxx;

xxx-xxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxxx;

3ß-xxxxxxx-5α-xxxxxxxxx-17-xx;

7α-xxxxxxx-XXXX;

7ß-xxxxxxx-XXXX;

7-xxxx-XXXX;

19-xxxxxxxxxxxxxx;

19-xxxxxxxxxxxxxxxxx.

2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:

Xxxxxxxxxxx; xxxxxxxxxx xxxxxxxxxx androgenových xxxxxxxxx (XXXX, xxxx. xxxxxxx, XXX-4033, ostarin x XXX140); xxxxxxx; xxxxxxx x xxxxxxxxxx, xxx xx x xxxxxxxx pouze na xx.

Xxx xxxxx skupiny xxxx xxxxx: * "xxxxxxxx" xx xxxxxxxx x xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx k xxxxx, xxxxxx tělo xxxxxxxx xxxxxxxxx xxxxxxxxx.

X2. XXXXXXXXX XXXXXXX, RŮSTOVÉ FAKTORY, XXXXXXXX XXXXX X XXXXXXXX

Xxxxxxxxxxx látky x xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx jsou xxxxxxxx:

1. Xxxxxxxxxxxxx (EPO) x xxxxxxxxxx xxxxxxxxxxx erytropoézu, xxxxxx, xxx ne x xxxxxxxx pouze xx xx:

1.1 Agonisté xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx

xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (EPO); xxxxxxxxxx xxxxxxxx xx XXX (EPO-Fc, methoxypolyethylenglykol-epoetin xxxx (XXXX)); EPO-mimetické xxxxxxxxxx a jejich xxxxxxxxxx (xxxx. CNTO 530 x xxxxxxxxxxx).

1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), xxxx.

xxxxx; xxxxxx; xxxxxxxxxx; xxxxxxxxxx (XX-4592); xxxxx.

1.3 Xxxxxxxxxx GATA, xxxx.

X-11706.

1.4 Xxxxxxxxxx XXX - xxxx (XXX - β), např.

luspatercept; xxxxxxxxxxx.

1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx. xxxx.

xxxxxx EPO; xxxxxxxxxxxxx XXX.

2. Xxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxxxxxx

2.1 Choriogonadotropin (XX) x xxxxxxxxxxxx hormon (XX) x jejich xxxxxxxxxx faktory, xxxx. xxxxxxxxx, deslorelin, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx x xxxxxxxxxxx, x xxxx.

2.2 Kortikotropiny a xxxxxx xxxxxxxxxx xxxxxxx, xxxx. kortikorelin.

2.3 Xxxxxxx xxxxxx (GH), xxxx xxxxxxxxx x xxxxxxxxxx xxxxxxx, xxxxxx, ale xx x omezením xxxxx na xx:

xxxxxxxxx xxxxxxxxx hormonu, např. XXX-9604 x hGH 176-191; xxxxxx xxxxxxxxxx xxxxxxx hormon (XXXX) x xxxx analoga, xxxx. XXX-1295, sermorelin x xxxxxxxxxxx; xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxxx x xxxxxxxx xxxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx x xxxxxxxxxxx; xxxxxxxxxx xxxxxxx xxxxxxxxx xxxxxxx (XXXX), xxxx. xxxxxxxxxxxx, GHRP-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, GHRP-5, XXXX-6 x hexarelin.

3. Růstové xxxxxxx x modulátory xxxxxxxxx xxxxxxx, xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxxxx růstové faktory (XXXx);

xxxxxxxxxxxx xxxxxxx faktor (XXX);

xxxxxxxx podobný xxxxxxx xxxxxx-1 (IGF-1) x xxxx analoga

mechanické růstové xxxxxxx (MGF);

růstový faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX);

xxxxxxxx- β4 x xxxx deriváty, xxxx. TB-500;

vaskulárně-endoteliární růstový xxxxxx (XXXX).

Xxxxx xxxxxxx xxxxxxx a modulátory xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx xxxxxxxx svalů, xxxxx x xxxxxx, xxxxxx xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových xxxxxx.

X3. XXXX2- XXXXXXXX

Xxxxxxx xxxxxxxxxx x xxxxxxxxxxxx xxxx-2 agonisté, xxxxxx xxxxx optických xxxxxxx, xxxx zakázáni.

Zahrnují (xxx xx x xxxxxxxx xxxxx xx xx):

Xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; indakaterol; xxxxxxxxxx; prokaterol; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; terbutalin; xxxxxxxxxxx; xxxxxxxxxx.

Xxxxxxxx jsou:

• inhalační xxxxxxxxxx: maximálně 1600 xxxxxxxxxx xx 24 xxxxx x xxxxxxxxxx xxxxxxx, xxxxxxxxxxxxxxxx 800 xxxxxxxxxx během xxxxxxx 12 hodin xx xxxxxxxxx xxxxx;
• xxxxxxxxx formoterol: xxxxxxxxx xxxxxx dávka 54 xxxxxxxxxx za 24 hodin;
• inhalační salmeterol: xxxxxxxxx 200 mikrogramů xx 24 xxxxx.

Xxxxxxxxxx xxxxxxxxxxx v moči x xxxxxxxxxxx vyšší xxx 1000 ng/ml x xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší než 40 xx/xx nebude xxxxxxxxxx za zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx studií, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxxxxxxxxxx xxxxxx (x xxxxxxxx) xxxxx, xxx výše xxxxxxx maximální xxxxx.

X4. XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

Xxxxxxxx xxxx xxxxxxxxxxx xxxxxxxxx x metabolické xxxxxxxxxx:

1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:

Xxxxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx);

xxxxxxxx-3,5-xxxx-7-17-xxxx (arimistan);

4-androsten-3,6,17-trion (6-xxx);

xxxxxxxxx;

xxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.

2. Xxxxxxxxxx xxxxxxxxxx estrogenových xxxxxxxxx (XXXX), xxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxx;

xxxxxxxxx, xxx ne x xxxxxxxx xxxxx xx xx.

3. Xxxxxxx xxxxxxxxxxxxxx xxxxx zahrnující:

Cyklofenil;

fulvestrant;

klomifen, xxx xx x xxxxxxxx xxxxx xx xx.

4. Xxxxx modifikující funkci(e) xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, ale ne x omezením xxxxx xx xx.

5. Metaboiické xxxxxxxxxx:

5.1 Aktivátory XXX-xxxxxxxxxx xxxxxxxxxxxxx (AMPK), např. XXXXX; a Xxxxxxxx Xxxxxxxxx xxxxx aktivovaného xxxxxxxxxxxxxx xxxxxxxxxxxxx (XXXXδ), xxxx. 2-(2-xxxxxx-4-((4-xxxxxx-2-(4-(xxxxxxxxxxxxxxx)xxxxxx)xxxxxxx-5-xx)xxxxxxxxxx)xxxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516);

5.2 xxxxxxxx a mimetika xxxxxxxx;

5.3 meldonium;

5.4 xxxxxxxxxxxx.

X5. XXXXXXXXX X XXXXXXXXX XXXXX

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxx látky xxxx xxxxxxxx, xxxxxx xxxx xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou x xxxxxxxxx xxxxxxxxxxxx xxxxxx.

Xxxxxxxx:

• Xxxxxxxxxxxx; xxxxxxxxxxxxxxx (xxxx. xxxxxxxxxx xxxxxx xxxxxxxx, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx); xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.

• Xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxxx; xxxxxxxxxxxx; indapamid; kanrenon; xxxxxxxx etakrynová; xxxxxxxxx; xxxxxxxxxxxxx; thiazidy (xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx); xxxxxxxxxx x xxxxxxx (xxxx. xxxxxxxxx), xxx xx x xxxxxxxx xxxxx na xx.

X xxxxxxxx:

• xxxxxxxxxxxx; pamabromu x xxxxxx podání inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxxx x brinzolamidu)

• Lokálního xxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxxx

Xxxxx jakéhokoliv množství xxxxx xx xxxxxxxxxx xxxxxxxx xxxxxxx (xx. xxxxxxxxxx, xxxxxxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x xxxxxxxxxxxxx) xx Vzorku Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Při Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx, bude xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx xxxx xxxxx xxxxx k xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxx.

XXXXXXXX METODY

M1. XXXXXXXXXX X KRVÍ X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Podání xxxx xxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxx (homologní) xxxx xxxxxxxxxxx xxxx xxxx červených xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxxx xxxxxxx.

2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx.

Xxxxxxxxxx:

xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx. xxxxxx xxxxxxxx xxxxxxxx na xxxxxxxxxxx x xxxxxxxxxxxxxxxxxx hemoglobiny), xxxxxxxxxxxxxxxxxxx x efaproxiral (XXX13), xxx xx x xxxxxxxx pouze xx xx. Xxxxxxxxx xxxxxxxxxxxx xxxxxxxx xxxxxxxx xxxx.

3. Xxxxxxxxx forma xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX A XXXXXXXXX XXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

1. Xxxxxxxxx, xxxx Xxxxx x Podvod, za xxxxxx xxxxxxx integritu x platnost Xxxxxx xxxxxxxxxx při Xxxxxxxxx xxxxxxxx. Xx zahrnuje xxxxxx x/xxxx xxxxxx (xxxx. xxxxxxxxxx) moči, xxx ne s xxxxxxxx pouze xx xx.

2. Nitrožilní infuze x/xxxx xxxxxxx více xxx xxxxxx 100 xx xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx x xxxxxxx nemocničních xxxxxxx, xxxxxxxxxxxxx xxxxxxx nebo xxxxxxxxxx xxxxxxxxxxxxxx metod.

M3. XXXXXX XXXXXX

X xxxxxx xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx výkonu je xxxxxxxx xxxxxxxxxxx:

1. Použití xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx;

2. Xxxxxxx geneticky xxxxxxxxxxxxx xxxxxxxxx, vytvořených k xxxxxxxxxxx xxxxxxxx xxxxxx x/xxxx x transkripční xxxx epigenetické xxxxxxxx xxxxxx exprese.

3. Xxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;

XXXXX X XXXXXX XXXXXXXX PŘI XXXXXXX

Xxxxx xxxxxxxxx X0 xx X5 a X1 xx M3 xxxxxxxxx výše

jsou Xxx Xxxxxxx xxxxxxxx x xxxxxxxxxxx xxxxxxx:

XXXXXXXX XXXXX

X6. XXXXXXXXXXX

Xxxxxxx xxxxxxxxxxx xxxxxx xxxxx xxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx, např. x- a I-, xxxx xxxxxxxx.

Xxxxxxxxxxx xxxxxxxx:

(x) Xxxxxxxxxxxx xxxxxxxxxxx:

Xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx /4-xxxxxxxxxxxxxx (xxxxxxxx)/;

xxxxxxxxxx;

xxxxxxxxxxx;

xxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx (x-);

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxxxx;

x-xxxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx.

Xxxxxxxxxxxx, které xxxx výslovně uvedeno x xxxxx xxxxxxxx, xx Xxxxxxxxxxx xxxxxx.

(x) Xxxxxxxxxx xxxxxxxxxxx.

Xxxxxxxx (ale xx s xxxxxxxx xxxxx xx xx):

Xxxxxxxxx (xxxxxxxxx)****;

xxxxxxxxxxx;

xxxxxxxxxxxxxxxxx;

1,3-xxxxxxxxxxxxxxxx;

xxxxxxx***;

xxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx x xxxx xxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxxxxx (parahydroxyamfetamin);

isomethepten;

katin**;

katinon x xxxx analoga (xxxx. xxxxxxxx, methedron x xxxx-xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxxxx***;

xxxxxxxxxxxxxxxxxxxxxxxx;

xxxxxxxxxxxx;

4-xxxxxxxxxx-2-xxxx (metylhexanamin);

niketamid;

norfenefrin;

oktopamin;

oxilofrin (xxxxxxxxxxxxx);

xxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxxxx;

xxxxxxxxxxxxx*****;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx);

xxxxxxxxxxxxx

x další látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky.

S xxxxxxxx:

• xxxxxxxxx

• xxxxxxxx xxxxxxxxx x případě xxxxxx xxxxxxxx/xxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Xxxxxxxxxxxxxx programu xxx xxx 2018*.

* Xxxxxxxxx, fenylefrin, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx x xxxxxxxx: Tyto xxxxx jsou xxxxxxxx xx Xxxxxxxxxxxxxx programu 2018 x nejsou xxxxxxxxxx xx Xxxxxxxx xxxxx.

** Xxxxx: xx xxxxxxxx xxxxx při xxxxxxxxxxx vyšší xxx 5 xxxxxxxxxx x 1 xx xxxx.

*** Xxxxxxx x xxxxxxxxxxxxx: xxxx zakázány xxx xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx v 1 xx xxxx.

**** Xxxxxxxxx (xxxxxxxxx): xxxx xxxxxxx xxx xxxxxxxx xxxxxx, xxxx. xxxxx, xxxx xxxxxxxx nebo xxxx xxxxxx společně x xxxxxxxxx anestetiky.

***** Xxxxxxxxxxxxx: xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x xxxx je xxxxx xxx 150 xxxxxxxxxx xx xxxxxxxx.

X7. XXXXXXXXX

Xxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxx:

Xxxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxxx(xxxxxx);

xxxxxxxx a jeho xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx.

X8. XXXXXXXXXXX

Xxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxx:

• Xxxxxxxx kanabinoidy, xxxx. xxxxx, xxxxxx x marihuana.

• Syntetické xxxxxxxxxxx, xxxx. xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxx kanabimimetika.

Kromě: xxxxxxxxxxxx

X9. XXXXXXXXXXXXXXX

Xxxxxxx glukokortikoidy xxxxxxxx xxxxxx, rektálně, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.

Xxxxxx, xxx xx x xxxxxxxx xxxxx xx xx:

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxxx.

XXXXX ZAKÁZANÉ V URČITÝCH XXXXXXXX

X1. BETA-BLOKÁTORY

Beta-blokátory jsou xxxxxxxx xxxxx x xxxxxxxxxxxxx xxxxxxxx Xxx Xxxxxxx, x xxx xx to označeno x Xxxx xxxxxx.

• Xxxxxxxxxxxx xxxxx (XXX)

• Xxxxxxxx (všechny xxxxxxxxxx) (WCBS)

• Golf (XXX)

• Xxxxxxxxxxx (XX)*

• Xxxxxxxx (XXX) - xxxxx xx xxxxxx x akrobatické xxxxxxxx-xxxxx x U-rampa, a xxxxxxxxx X-xxxxx x "xxx xxx"

• Xxxxxxxx xxxxxx (xxxxxxxxx xxxxxxxx) (XXXX) x disciplínách xxxxxxxxxx xxxx x xxxxxxxxx xxxx xxx xxxxxxx, xxxxxxxxx xxxxx x xxxxxxxxx nebo xxx xxxxxxx, xxxx xxxxxxxxx, xxxx blue, xxxxxxxxxxxx, xxxxxxxx xxxxx, xxxxxxx xxxxxxxx na xxxx x variabilní xxxx.

• Xxxxxxx (XXXX, IPC)*

• Šipky (XXX)

* Xxxxxxxx xxxx Xxxx xxxxxx

Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:

Xxxxxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxx;

xxxxxxxxxx;

xxxxxxxxx;

xxxxxxxxxxx;

xxxxxxxxxxxx;

xxxxxxxxxx;

xxxxxxx;

xxxxxxxxxx;

xxxxxxxx;

xxxxxxxxxxx;

xxxxxxx;

xxxxxxx;

xxx xx x xxxxxxxx xxxxx xx xx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 36/2019 Xx. m. x. xxxxx účinnosti xxxx 26.7.2019.

Xxxxxx xxxxxxx x. 36/2019 Sb. x. x. xxx xxxxxx právním předpisem č. 32/2023 Sb. m. s. x účinností xx 22.8.2023.

Xxxxx jednotlivých xxxxxxxx norem jiných xxxxxxxx předpisů x xxxxxxxx není aktualizováno, xxxxx xx xxxx xxxxxx xxxxxxxxx xxxxx xxxxx xxxxxxxxx právního xxxxxxxx.

1) Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx, přijatá xxx 19. xxxxx 2005 x Paříži, byla xxxxxxxxx x xxxxxxxxx xxxxx x x xxxxxxxxx do xxxxxxx xxxxxx xxx č. 58/2007 Sb. m. s.

Xxxx xxxxx překladu Xxxxxx xx xxxxxxx jazyka xxxx xxxxxxxxx xxx č. 46/2008 Sb. m. s.